Integral Diagnostics Reports 25% Revenue Growth and Appoints New CFO
Integral Diagnostics (ASX:IDX) posted strong preliminary FY26 results with revenue nearing $790 million and operating EBITDA up 30%, while announcing Jenny Martin as incoming CFO amid leadership transitions.
- FY26 revenue expected around $788m-$790m, up 25%
- Operating EBITDA forecast at $164m-$165m, 30% increase
- Operating NPAT projected to rise 50% to $47m-$48m
- Net debt to EBITDA ratio improves to 2.3x
- Jenny Martin appointed CFO, succeeding Craig White
Robust Financial Performance Underpins Growth Phase
Integral Diagnostics (IDX) is delivering a strong finish to FY26, with preliminary results showing revenue climbing to approximately $788 million to $790 million, a 25% jump on the prior year’s $628 million. Operating EBITDA is expected to reach $164 million to $165 million, up 30%, while the operating NPAT is set to nearly double, rising 50% to between $47 million and $48 million. These gains come on the back of a full 12-month contribution from Capitol Health, compared to just six months in FY25, reflecting successful integration and scale benefits.
The operating EBITDA margin is also nudging higher, forecast at about 20.8% to 21.0%, up around 80 basis points from last year’s 20.1%. This margin expansion aligns with IDX’s FY26 guidance and underscores effective operational discipline amid growth.
Balance Sheet Strength and Capital Discipline
Net debt to operating EBITDA has improved to an estimated 2.3 times as of 30 June 2026, down from 2.6 times a year earlier. This signals a continued de-gearing trajectory and financial prudence during a period of expansion. Capital expenditure for the year was approximately $50 million, comfortably within the company’s guidance range of $45 million to $55 million, supporting both replacement and growth initiatives.
Leadership Transition with New CFO Appointment
Integral Diagnostics is also advancing its leadership team with the appointment of Jenny Martin as incoming Chief Financial Officer. Martin officially joins the company immediately in a transitional capacity and will formally assume the CFO role on 5 October 2026. She brings over 25 years of experience in healthcare technology and finance, having held senior roles at The Citadel Group Limited (ASX:CGL) and other ASX 200 companies. Her expertise in managing complexity and rapid growth is expected to complement the strategic direction set by new CEO Jason Martinez, who began his tenure earlier in August.
Martin replaces Craig White, who is retiring after 4½ years as CFO. White has been credited with transforming IDX’s finance, risk, and legal functions and will support the handover until the end of October 2026 before retiring in April 2027. IDX Chair Toby Hall praised White’s leadership and acknowledged the strong foundations laid alongside outgoing CEO Ian Kadish.
Upcoming Audited Results and Investor Engagement
The preliminary figures remain subject to final audit and year-end procedures, with audited FY26 results scheduled for release on 25 August 2026. As part of the leadership transition, CEO Jason Martinez and outgoing CFO Craig White will present the results and engage with investors, marking a key milestone in IDX’s next growth phase.
Bottom Line?
Integral Diagnostics’ FY26 preliminary results and CFO appointment signal a well-managed growth trajectory, but investors will watch closely for the audited results and how new leadership shapes future strategy.
Questions in the middle?
- How will Jenny Martin’s leadership influence IDX’s financial strategy and growth plans?
- Can IDX sustain margin improvements amid ongoing integration and expansion?
- What guidance will the company provide alongside the audited FY26 results on 25 August?
